Stem Point Capital LP Madrigal Pharmaceuticals, Inc. Transaction History
Stem Point Capital LP
- $314 Billion
- Q1 2025
A detailed history of Stem Point Capital LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 40,936 shares of MDGL stock, worth $14.2 Million. This represents 4.32% of its overall portfolio holdings.
Number of Shares
40,936Holding current value
$14.2 Million% of portfolio
4.32%Shares
2 transactions
Others Institutions Holding MDGL
# of Institutions
365Shares Held
23.2MCall Options Held
979KPut Options Held
432K-
Janus Henderson Group PLC London, X02.21MShares$763 Million0.42% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.1MShares$726 Million39.89% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.02MShares$699 Million10.84% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$689 Million10.82% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$683 Million7.8% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.91B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...